Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study

December 14, 15.00-15.30

Narguess Askari, PharmD                                                                                   


  • Review the high unmet need in cervical cancer
  • Educate on tisotumab vedotin MOA
  • Discuss tisotumab vedotin data in recurrent and/or metastatic cervical cancer (innovaTV 201 + innovaTV 204)
  • Provide an overview of TV clinical development plans